No Data
No Data
No Data
Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics)
Yahoo Finance20minutes ago
Sage Therapeutics to Participate in Upcoming May Investor Conferences
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor
BusinesswireMay 7 06:30 ET
Sage Therapeutics Is Maintained at Overweight by JP Morgan
Sage Therapeutics Is Maintained at Overweight by JP Morgan
Dow JonesMay 1 11:33 ET
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28
JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $29 to $28.
BenzingaMay 1 11:24 ET
Express News | Sage Therapeutics Inc : JP Morgan Cuts Target Price to $28 From $29
ReutersApr 30 23:44 ET
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
Yahoo FinanceApr 30 12:57 ET
taijahmed75OP : Adding the link here: These Five Biotech Stocks Are Developing Potentially Groundbreaking Mental Health Treatments